Arcturus Therapeutics Holdings (ARCT) Operating Expenses (2018 - 2026)
Arcturus Therapeutics Holdings' (ARCT) quarterly Operating Expenses came in at -$2.0 million in Q1 2026, down 104.26% YoY from $46.2 million in Q1 2025, and up 11.71% on a QoQ basis from -$2.2 million in Q4 2025.
Arcturus Therapeutics Holdings (ARCT) Operating Expenses (2018 - 2026) Analysis & Trends
Arcturus Therapeutics Holdings (ARCT) has 9 years of Operating Expenses data on file, last reported at -$2.0 million in Q1 2026.
- Quarterly Operating Expenses fell 104.26% year-over-year to -$2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $32.7 million (down 90.78% YoY) and the FY2025 annual result came in at -$10.5 million, down 104.22% from the prior year.
- Operating Expenses climbed to -$2.0 million in Q1 2026, from -$2.2 million in the prior quarter.
- In the past five years, Operating Expenses ranged from a high of $259.3 million in Q4 2024 to a low of -$3.9 million in Q2 2024.
- A 5-year average of $52.6 million and a median of $49.2 million in 2022 frame the typical range for Operating Expenses.
- Annual changes were most pronounced in 2024 — Operating Expenses tumbled 105.93% — and 2025, when it soared 1120.9%.
- Tracing ARCT's Operating Expenses over 5 years: stood at $38.8 million in 2022, then advanced by 26.48% to $49.1 million in 2023, then surged by 427.85% to $259.3 million in 2024, then tumbled by 100.86% to -$2.2 million in 2025, then climbed by 11.71% to -$2.0 million in 2026.
- The last three Operating Expenses figures came in at -$2.0 million (Q1 2026), -$2.2 million (Q4 2025), and -$3.1 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 2.09 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 3.00 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 2.89 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 505.13 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.21 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 4,978.15 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 541.02 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.06 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 427.03 Mn |
| 10 | Arcturus Therapeutics Holdings | 233.92 Mn | 42.44 Mn | - | 28.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 28.50 Mn |
| Mar 31, 2026 | -1.97 Mn |
| Dec 31, 2025 | -2.23 Mn |
| Sep 30, 2025 | -3.06 Mn |
| Jun 30, 2025 | 39.92 Mn |
| Mar 31, 2025 | 46.21 Mn |
| Dec 31, 2024 | 259.32 Mn |
| Sep 30, 2024 | 52.41 Mn |
| Jun 30, 2024 | -3.91 Mn |
| Mar 31, 2024 | 68.42 Mn |
| Dec 31, 2023 | 49.13 Mn |
| Sep 30, 2023 | 64.45 Mn |
| Jun 30, 2023 | 65.89 Mn |
| Mar 31, 2023 | 65.53 Mn |
| Dec 31, 2022 | 38.84 Mn |
| Sep 30, 2022 | 50.18 Mn |
| Jun 30, 2022 | 49.18 Mn |
| Mar 31, 2022 | 55.62 Mn |
| Dec 31, 2021 | 43.44 Mn |
| Sep 30, 2021 | 56.26 Mn |